Literature DB >> 17239310

Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy.

Allan J Pantuck, Nazy Zomorodian, Arie S Belldegrun.   

Abstract

Entities:  

Year:  2007        PMID： 17239310     DOI： 10.1007/s11934-007-0014-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  5 in total

1.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.

Authors:  M W Kattan; T M Wheeler; P T Scardino
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  A catalog of prostate cancer nomograms.

Authors:  P L Ross; P T Scardino; M W Kattan
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

Review 3.  Contemporary management of prostate cancer with lethal potential.

Authors:  John W Davis; Mark E Shaves; Paul F Schellhammer
Journal:  Oncology (Williston Park)       Date:  2004-06       Impact factor: 2.990

4.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

5.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.

Authors:  W J Catalona; D S Smith
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450
  5 in total
  5 in total

Review 1.  Recent developments in prostate cancer biomarker research: therapeutic implications.

Authors:  Sujitra Detchokul; Albert G Frauman
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

Authors:  Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria J Sinibaldi; Janet S Walczak; Samuel R Denmeade
Journal:  Cancer Biol Ther       Date:  2007-06-05       Impact factor: 4.742

3.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

4.  RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.

Authors:  Kilian M Gust; Matthias D Hofer; Sven R Perner; Robert Kim; Arul M Chinnaiyan; Sooryanarayana Varambally; Peter Moller; Ludwig Rinnab; Mark A Rubin; Jochen Greiner; Michael Schmitt; Rainer Kuefer; Mark Ringhoffer
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

Review 5.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.